卡维地洛对慢性充血性心力衰竭患者血清基质金属蛋白酶-2、9、10水平的影响及疗效观察

探讨卡维地洛对慢性充血性心力衰竭（CHF）患者血清基质金属蛋白酶-2、9、10水平的影响及其疗效。方法：76例CHF患者随机分为观察组与对照组。两组患者均予以强心（地高辛）、利尿（噻嗪类）和扩张血管（硝酸酯类）等常规治疗。观察组在此基础上加用卡维地洛片治疗，连用6个月。观察两组患者治疗前和治疗6个月后患者血清MMP-2、9、10水平变化，并进行疗效及安全性观察。结果：治疗6个月后，两组血清MMP-2、9、10水平均有明显下降（P〈0．05），且观察组各指标较对照组下降更显著（P〈0．05）；同时观察组总有效率为94．74％，明显高于对照组的78．75％（P〈0．05）。结论：卡维地洛治疗CHF具有良好的疗效和安全性，作用机制可能与降低血清MMP-2、9、10水平密切相关。

Influence and Curative Effect Observation of Carvedilol on Serum Matrix Metalloproteinase -2, 9 and 10 (MMP-2, 9 and 10) in Patients with Chronic Congestive Heart Failure

To study the influence and curative effect of carvedilol on serum matrix metalloproteinase 2, 9 and 10 （ MMP-2, 9 and 10） in the pati6nts with chroniccongestive heart failure （CHF）. Methods： Totally 76 patients with CHF were selected and randomly divided into the observation group and the control group. All the patients were given routine medical treatment, including cardiotonic treatment （digoxin）, diuresis （thiadiazide）, vascular dilation （nitrate ester） and so on. The patients in the observation group were additionally given carvedilol for 6 months. The changes of serum MMP-2, 9 and 10 levels in the patients before the treatment and 6 months after the medical treatment were observed, and the curative effect and safety were studied as well. Results： After the 6-month medical treatment, the serum MMP2, 9 and 10 levels in all the patients were obviously declined （P 〈 0.05 ）, and the declining rates in the observation group were much higher than those in the control group（ P 〈 0.05 ）. Meanwhile, the total clinical efficiency of the observation group was 94.74%, which was higher than that of the control group （78.95%） （ P 〈0, 05 ）. Conclusion： Carvedilol has favorable curative effect and safety in the treatment of CIF, and the underlying mechanism may be relative to the decrease of serum MMP-2, 9 and 10 levels.